CN106676089B - Method for preparing human prothrombin complex from blood plasma - Google Patents
Method for preparing human prothrombin complex from blood plasma Download PDFInfo
- Publication number
- CN106676089B CN106676089B CN201710118663.7A CN201710118663A CN106676089B CN 106676089 B CN106676089 B CN 106676089B CN 201710118663 A CN201710118663 A CN 201710118663A CN 106676089 B CN106676089 B CN 106676089B
- Authority
- CN
- China
- Prior art keywords
- plasma
- gel
- eluent
- chromatographic column
- washing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6429—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
Abstract
The invention discloses a method for preparing a human prothrombin complex from blood plasma. The invention adopts DEAE A-50 gel to directly adsorb the human prothrombin complex from blood plasma, the A-50 gel after adsorption is filled in a fixed bed chromatographic column, the filled chromatographic column uses a peristaltic pump to pump eluent for on-line washing and elution, the eluent is inactivated by S/D, and the high-purity human prothrombin complex product is obtained by secondary chromatography and purification of the fixed bed chromatographic column. The method realizes the accurate control of the elution flow and speed through the on-line elution of the gel packed column, reduces the problems of pollution, cross contamination, gel leakage and the like caused by open operation, and has higher product purity, the potency of the factor IX can reach more than 27IU/ml, and the specific activity of the factor IX can reach more than 0.8IU/mg protein. Meanwhile, the self-flushing type filter with the pressure difference controller and the solid automatic stripping system is adopted, so that the pressure difference in the whole filtering process is stable and controllable, gel particles are well protected, broken rubber particles flowing into a plasma tank in the filtering process are obviously reduced, and the gel loss in the production process can be reduced by more than 20%.
Description
Technical Field
The invention belongs to the technical field of biological pharmacy and blood products, and particularly relates to a method for preparing a human prothrombin complex from blood plasma in the preparation of the blood products.
Background
Human Prothrombin complex (PCC) is derived from the plasma of healthy people, is a traditional plasma protein preparation, and can be used for treating hemorrhage and the like caused by vitamin K deficiency or liver disease besides hemophilia b, and the use amount of PCC is increased year by year with the gradual approval of clinicians. At present, few manufacturers for producing PCC in China are in shortage of raw material plasma, and PCC is in serious shortage, so that production and preparation of PCC attract attention in various aspects.
The current classical process for preparing human prothrombin complex is a batch adsorption process proposed by the Netherlands red cross blood center, wherein four coagulation factors II, VII, IX and X are adsorbed from raw plasma by using a weak anion exchanger such as sephadex DEAE A-50, the adsorbed A-50 gel is taken out in batches by using a filter screen, a buffer solution with low ionic strength is used for washing to remove the foreign proteins with weak adsorption force and other adhered components, then the ionic strength of the buffer solution is increased to elute the required proteins, and the subsequent processing treatment is carried out. The batch adsorption process is an open operation, is complex to operate, and easily causes the problems of pollution, cross contamination, gel leakage and the like. The domestic human prothrombin complex is also reported to be prepared by taking the component III of the cohn method as a starting material, but the method is easy to generate prothrombin activation phenomenon, causes the coagulation reaction of a patient and has great potential safety hazard.
Disclosure of Invention
The invention provides a preparation method for directly adsorbing a human prothrombin complex from blood plasma by DEAE A-50 gel, filling the adsorbed A-50 gel into a fixed bed chromatographic column, pumping eluent into the filled chromatographic column by using a peristaltic pump for on-line washing and elution, inactivating the eluent by S/D, directly diluting an inactivation solution to a conductance value of less than 1000us without dialysis concentration, and then carrying out secondary chromatography and purification by using the fixed bed chromatographic column to obtain a high-purity human prothrombin complex product.
The purpose of the invention is realized by the following technical scheme:
there is provided a method for preparing a human prothrombin complex from plasma, comprising the steps of:
(1) removal of plasma cryoprecipitate: taking fresh frozen human plasma as a raw material, and removing cryoprecipitate in the plasma through plasma melting, plasma mixing and continuous centrifugation processes to obtain plasma centrifugal supernatant without cryoprecipitate;
(2) gel batch adsorption: controlling the plasma temperature at 10-15 deg.C, adding balanced DEAE A-50 gel into the plasma without cryoprecipitate according to 1.0-1.5g xerogel/L plasma, stirring for 45min, stopping stirring, standing for 45 min; filtering the plasma after gel adsorption by using a self-washing continuous filter with a pressure difference controller and a solid automatic stripping system, collecting the A-50 gel after adsorption, and merging the filtered plasma liquid into a plasma tank;
(3) and (3) loading and eluting the column: filling the adsorbed A-50 gel in a fixed bed chromatographic column, pumping a washing solution into the filled chromatographic column by using a peristaltic pump for online washing, wherein the flow rate of the washing solution is 30-40cm/h, and the washing time is 60-90 min; pumping the washed A-50 gel into eluent by using a peristaltic pump to carry out online elution, wherein the flow rate of the eluent is 30-40cm/h, stopping elution when the ultraviolet absorption value in an online ultraviolet detector is lower than 500Au, collecting the eluent and filtering by using a 0.45um filter element;
(4) S/D inactivation and dilution: slowly adding the prepared S/D inactivation solution into the filtered eluent under mild stirring, and stirring for 30min after the addition is finished; adjusting the temperature of the solution to 24-26 ℃, and inactivating for 6 h; after inactivation, reducing the conductance value to 800-1000us by adopting a method of adding diluent for dilution;
(5) fixed bed column chromatography: filling capto DEAE anion exchange gel in a fixed bed chromatographic column, balancing the filled chromatographic column by using a balance liquid for 2-5 column volumes, using a peristaltic pump chromatographic column for the diluent after S/D inactivation, and enabling the sample loading flow rate to be 30-40 cm/h; pumping cleaning solution by using a peristaltic pump for online washing after the sample loading is finished, wherein the flow rate of the cleaning solution is 30-40cm/h, and the washing time is 60-90 min; pumping eluent into the washed chromatographic column by using a peristaltic pump for elution, wherein the flow rate of the eluent is 30-40cm/h, stopping elution when the ultraviolet absorption value in an online ultraviolet detector is lower than 500Au, collecting the eluent and filtering by using a 0.45um filter element;
(6) and (3) ultrafiltration concentration: performing ultrafiltration dialysis by using dialysate, performing ultrafiltration concentration after the conductance value of a dialyzate port is lower than 1000us, and controlling the titer of the concentrated solution to be more than 35 IU/ml;
(7) preparing liquid: diluting the ultrafiltration concentrate with dialysate, adjusting activity to 30-40IU/ml, pH to 7-7.5, and filtering with 0.45um filter element;
(8) subpackaging;
(9) freeze-drying;
and (3) filtering the plasma after gel adsorption in the step (2) by using a self-flushing type filter, wherein the self-flushing type filter is a self-flushing type continuous filter with a pressure difference controller and an automatic solid matter stripping system.
The washing solution in the step (3) consists of 20-30mmol/L sodium citrate, 0.1-0.5mol/L sodium chloride and 200-500IU/ml heparin sodium, and the pH value is 6.8-7.0. The eluent comprises 20-30mmol/L sodium citrate, 0.5-1.0mol/L sodium chloride and 200-500IU/ml heparin sodium, and the pH value is 6.8-7.0.
And (3) the elution mode in the step (3) is to fill the adsorbed A-50 gel in a fixed bed chromatographic column, and pump eluent into the filled chromatographic column by using a peristaltic pump to carry out online washing and elution.
The way of reducing the conductance value to 800-1000us after the inactivation in the step (4) is to add diluent for dilution according to the ratio of 1: 2.
Compared with the prior art, the invention has the following beneficial effects;
1. at present, the human prothrombin compound is extracted from blood plasma by using sephadex DEAE A-50 gel batch adsorption-elution-concentration-secondary batch adsorption-secondary concentration-split charging-freeze-drying method, and the batch adsorption process is open operation, so that the problems of pollution, cross contamination, gel leakage and the like are easily caused. The invention fills the adsorbed A-50 gel in the fixed bed chromatographic column, and the filled chromatographic column uses a peristaltic pump to pump eluent for on-line washing and elution, thereby reducing the problems of pollution, cross contamination, gel leakage and the like caused by open operation. The online elution realizes the accurate control of the elution flow and speed, so that the whole process is more controllable, meanwhile, the online ultraviolet detector of the fixed bed chromatography system ensures that the collection of the target protein is more efficient in the elution process, the mixing of the hybrid protein is reduced, the purity of the obtained product is higher, the potency of the factor IX can reach more than 27IU/ml, and the specific activity of the factor IX can reach more than 0.8IU/mg protein.
2. The method adopted in the invention for filtering the plasma added with the gel is different from the traditional single filter screen filtering, when the single filter screen filters, the filtering pressure difference can be increased along with the increase of the solid concentration, the fragile sephadex gel can be damaged by the overhigh pressure difference, the material loss in the production process is increased, and the broken colloidal particles can cause adverse effect on the subsequent production of the serum albumin and the serum albumin after flowing into the plasma tank. By improving the process, the self-flushing continuous filter with the pressure difference controller and the solid automatic stripping system is adopted to filter the plasma added with the gel, so that the production time cost is greatly saved, the pressure difference in the whole filtering process is stable and controllable, the gel particles are well protected, the broken rubber particles flowing into a plasma tank in the filtering process are obviously reduced, and the gel loss in the production process can be reduced by more than 20%.
3. In the traditional process, after S/D inactivation, the conductivity value of the eluent is reduced to 800-.
Drawings
FIG. 1 is a process flow diagram for the preparation of human prothrombin complex from plasma;
Detailed Description
The features and advantages of the present invention will be further understood from the following detailed description taken in conjunction with the accompanying drawings. The examples provided are merely illustrative of the method of the present invention and do not limit the remainder of the disclosure in any way.
[ example 1 ]
Removal of plasma cryoprecipitate: taking fresh frozen human plasma as a raw material, and removing cryoprecipitate in the plasma through plasma melting, plasma mixing and continuous centrifugation processes to obtain 2kg of plasma centrifugal supernatant without cryoprecipitate;
gel batch adsorption: controlling the plasma temperature at 10 ℃, adding the balanced DEAE A-50 gel into the plasma after the cold precipitation according to 1.0g of xerogel/L plasma, stirring and adsorbing for 45min, and then closing the stirring. Filtering the plasma after gel adsorption by using a self-flushing filter, collecting the A-50 gel after adsorption, and merging the plasma filtrate into a plasma tank;
and (3) loading and eluting the column: and filling the adsorbed A-50 gel in a fixed bed chromatographic column, pumping a washing solution into the filled chromatographic column by using a peristaltic pump to carry out online washing, wherein the flow rate of the washing solution is 35cm/h, and the washing time is 60 min. Pumping the washed A-50 gel into eluent by using a peristaltic pump to carry out online elution, wherein the flow rate of the eluent is 35cm/h, stopping elution when the ultraviolet absorption value in an online ultraviolet detector is lower than 500Au, collecting 140ml of the eluent, and filtering by using a 0.45um filter element;
S/D inactivation and dilution: slowly adding the prepared S/D inactivation solution into the filtered eluent under mild stirring, and stirring for 30min after the addition is finished. Adjusting the temperature of the solution to 24-26 ℃, and inactivating for 6 h. After inactivation, adding 280ml of diluent to reduce the conductance value to 800 us;
fixed bed column chromatography: and filling capto DEAE anion exchange gel in a fixed bed chromatographic column, balancing the filled chromatographic column by using a balance liquid for 3 column volumes, and using a peristaltic pump chromatographic column for the diluent after S/D inactivation, wherein the sample loading flow rate is 35 cm/h. And pumping washing liquid by using a peristaltic pump to perform online washing after the sample loading is finished, wherein the flow rate of the washing liquid is 35cm/h, and the washing time is 60 min. Pumping eluent into the washed chromatographic column by using a peristaltic pump for elution, wherein the flow rate of the eluent is 35cm/h, stopping elution when the ultraviolet absorption value in the online ultraviolet detector is lower than 500Au, and collecting the eluent;
ultrafiltration and dialysis: and (3) carrying out ultrafiltration dialysis by using dialysate, carrying out ultrafiltration concentration after the conductance value of a dialyzate port is lower than 1000us, and controlling the titer of the concentrated solution to be more than 35IU/ml to obtain 75ml of human prothrombin complex stock solution.
[ example 2 ]
Removal of plasma cryoprecipitate: taking fresh frozen human plasma as a raw material, and removing cryoprecipitate in the plasma through plasma melting, plasma mixing and continuous centrifugation processes to obtain 2kg of plasma centrifugal supernatant without cryoprecipitate;
gel batch adsorption: controlling the plasma temperature at 15 ℃, adding the balanced DEAE A-50 gel into the plasma after the cold precipitation according to 1.5g of xerogel/L plasma, stirring and adsorbing for 45min, then closing the stirring, and standing and settling for 45 min. Filtering the plasma after gel adsorption by using a self-flushing filter, collecting the A-50 gel after adsorption, and merging the plasma filtrate into a plasma tank;
and (3) loading and eluting the column: and filling the adsorbed A-50 gel in a fixed bed chromatographic column, pumping a washing solution into the filled chromatographic column by using a peristaltic pump to carry out online washing, wherein the flow rate of the washing solution is 40cm/h, and the washing time is 70 min. Pumping the washed A-50 gel into eluent by using a peristaltic pump to carry out online elution, wherein the flow rate of the eluent is 40cm/h, stopping elution when the ultraviolet absorption value in an online ultraviolet detector is lower than 500Au, and collecting 170ml of the eluent;
S/D inactivation and dilution: slowly adding the prepared S/D inactivation solution into the filtered eluent under mild stirring, and stirring for 30min after the addition is finished. Adjusting the temperature of the solution to 24-26 ℃, and inactivating for 6 h. After inactivation, 340ml of diluent is added to reduce the conductance value to 800 us;
fixed bed column chromatography: and filling capto DEAE anion exchange gel in a fixed bed chromatographic column, balancing 5 column volumes of the filled chromatographic column by using a balance liquid, and using a peristaltic pump chromatographic column for the diluent after S/D inactivation, wherein the sample loading flow rate is 40 cm/h. And pumping washing liquid by using a peristaltic pump to perform online washing after the sample loading is finished, wherein the flow rate of the washing liquid is 40cm/h, and the washing time is 70 min. Pumping eluent into the washed chromatographic column by using a peristaltic pump for elution, wherein the flow rate of the eluent is 40cm/h, stopping elution when the ultraviolet absorption value in the online ultraviolet detector is lower than 500Au, and collecting the eluent;
ultrafiltration and dialysis: and (3) carrying out ultrafiltration dialysis by using dialysate, carrying out ultrafiltration concentration after the conductance value of a dialyzate port is lower than 1000us, and controlling the titer of the concentrated solution to be more than 35IU/ml to obtain 85ml of human prothrombin complex stock solution. Subpackaging and freeze-drying to obtain the PCC product. The detection shows that the titer of factor IX of the obtained PCC product is more than 27IU/ml, and the specific activity of the factor IX is more than 0.8IU/mg protein.
Claims (5)
1. A method for preparing a human prothrombin complex from plasma comprising the steps of:
(1) removal of plasma cryoprecipitate: taking fresh frozen human plasma as a raw material, and removing cryoprecipitate in the plasma through plasma melting, plasma mixing and continuous centrifugation processes to obtain plasma centrifugal supernatant without cryoprecipitate;
(2) gel batch adsorption: controlling the temperature of the plasma at 10-15 ℃, adding balanced DEAE-sephadex A-50 gel into the plasma without cryoprecipitate according to 1.0-1.5g xerogel/L plasma, stirring and adsorbing for 45min, then closing stirring, and standing and settling for 45 min; filtering the plasma after gel adsorption by using a self-washing continuous filter with a pressure difference controller and a solid automatic stripping system, collecting the A-50 gel after adsorption, and merging the filtered plasma liquid into a plasma tank;
(3) and (3) loading and eluting the column: filling the adsorbed A-50 gel in a fixed bed chromatographic column, pumping a washing solution into the filled chromatographic column by using a peristaltic pump for online washing, wherein the flow rate of the washing solution is 30-40cm/h, and the washing time is 60-90 min; pumping the washed A-50 gel into eluent by using a peristaltic pump to carry out online elution, wherein the flow rate of the eluent is 30-40cm/h, stopping elution when the ultraviolet absorption value in an online ultraviolet detector is lower than 500Au, collecting the eluent and filtering by using a 0.45um filter element;
(4) S/D inactivation and dilution: slowly adding the prepared S/D inactivation solution into the filtered eluent under mild stirring, and stirring for 30min after the addition is finished; adjusting the temperature of the solution to 24-26 ℃, and inactivating for 6 h; after inactivation, reducing the conductance value to 800-1000us by adopting a method of adding diluent for dilution;
(5) fixed bed column chromatography: filling capto DEAE anion exchange gel in a fixed bed chromatographic column, balancing the filled chromatographic column by using a balance liquid for 2-5 column volumes, using a peristaltic pump chromatographic column for the diluent after S/D inactivation, and enabling the sample loading flow rate to be 30-40 cm/h; pumping cleaning solution by using a peristaltic pump for online washing after the sample loading is finished, wherein the flow rate of the cleaning solution is 30-40cm/h, and the washing time is 60-90 min; pumping eluent into the washed chromatographic column by using a peristaltic pump for elution, wherein the flow rate of the eluent is 30-40cm/h, stopping elution when the ultraviolet absorption value in an online ultraviolet detector is lower than 500Au, collecting the eluent and filtering by using a 0.45um filter element;
(6) and (3) ultrafiltration concentration: performing ultrafiltration dialysis by using dialysate, performing ultrafiltration concentration after the conductance value of a dialyzate port is lower than 1000us, and controlling the titer of the concentrated solution to be more than 35 IU/ml;
(7) preparing liquid: diluting the ultrafiltration concentrate with dialysate, adjusting activity to 30-40IU/ml, pH to 7-7.5, and filtering with 0.45um filter element;
(8) subpackaging;
(9) and (5) freeze-drying.
2. The method according to claim 1, wherein the plasma after gel adsorption in step (2) is filtered by a self-washing type continuous filter having a pressure difference controller and an automatic solid matter removing system.
3. The method for preparing human prothrombin complex from plasma according to claim 1, wherein the washing solution in step (3) is composed of 20-30mmol/L sodium citrate, 0.1-0.5mol/L sodium chloride, 200-500IU/ml heparin sodium, pH 6.8-7.0; the eluent comprises 20-30mmol/L sodium citrate, 0.5-1.0mol/L sodium chloride and 200-500IU/ml heparin sodium, and the pH value is 6.8-7.0.
4. The method of claim 1, wherein the elution in step (3) is performed by loading the adsorbed A-50 gel into a fixed bed column, and the loaded column is washed and eluted on-line by pumping the eluent with a peristaltic pump.
5. The method for preparing human prothrombin complex from plasma according to claim 1, wherein the conductivity value is decreased to 800-1000us after the inactivation in step (4) by adding diluent at a ratio of 1:2 for dilution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710118663.7A CN106676089B (en) | 2017-03-01 | 2017-03-01 | Method for preparing human prothrombin complex from blood plasma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710118663.7A CN106676089B (en) | 2017-03-01 | 2017-03-01 | Method for preparing human prothrombin complex from blood plasma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106676089A CN106676089A (en) | 2017-05-17 |
| CN106676089B true CN106676089B (en) | 2020-01-10 |
Family
ID=58861631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710118663.7A Active CN106676089B (en) | 2017-03-01 | 2017-03-01 | Method for preparing human prothrombin complex from blood plasma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106676089B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108048433B (en) * | 2018-01-19 | 2020-07-21 | 贵州泰邦生物制品有限公司 | Preparation method of human prothrombin complex |
| CN108245986B (en) * | 2018-03-24 | 2020-03-24 | 广东双林生物制药有限公司 | A plasma adsorption and filtration device for production of blood coagulation factor class blood products |
| CN108441490B (en) * | 2018-04-02 | 2021-11-30 | 博雅生物制药集团股份有限公司 | Process for preparing human prothrombin complex by flow adsorption method |
| CN109593747B (en) * | 2018-12-25 | 2021-08-10 | 山东泰邦生物制品有限公司 | Method for liquid storage of human prothrombin complex intermediate product |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101974070A (en) * | 2010-11-08 | 2011-02-16 | 江西博雅生物制药股份有限公司 | Preparation process of human prothrombin compound |
| CN102604920A (en) * | 2012-04-06 | 2012-07-25 | 湖南紫光古汉南岳制药有限公司 | Preparation method of human prothrombin complex |
| CN102614219A (en) * | 2012-04-06 | 2012-08-01 | 湖南紫光古汉南岳制药有限公司 | Method for preparing human prothrombin complex with high yield |
| CN104109202A (en) * | 2014-07-17 | 2014-10-22 | 山东泰邦生物制品有限公司 | Method for adsorbing human prothrombin complex from plasma |
| CN104672328A (en) * | 2015-02-13 | 2015-06-03 | 山东泰邦生物制品有限公司 | Production method of human antithrombin III |
| CN105039295A (en) * | 2015-09-15 | 2015-11-11 | 上海洲跃生物科技有限公司 | Method for preparing human thrombin from cold-removing glue plasma |
| CN105175486A (en) * | 2015-10-20 | 2015-12-23 | 上海洲跃生物科技有限公司 | Preparation method of high-purity human coagulation factor IX |
-
2017
- 2017-03-01 CN CN201710118663.7A patent/CN106676089B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101974070A (en) * | 2010-11-08 | 2011-02-16 | 江西博雅生物制药股份有限公司 | Preparation process of human prothrombin compound |
| CN102604920A (en) * | 2012-04-06 | 2012-07-25 | 湖南紫光古汉南岳制药有限公司 | Preparation method of human prothrombin complex |
| CN102614219A (en) * | 2012-04-06 | 2012-08-01 | 湖南紫光古汉南岳制药有限公司 | Method for preparing human prothrombin complex with high yield |
| CN104109202A (en) * | 2014-07-17 | 2014-10-22 | 山东泰邦生物制品有限公司 | Method for adsorbing human prothrombin complex from plasma |
| CN104672328A (en) * | 2015-02-13 | 2015-06-03 | 山东泰邦生物制品有限公司 | Production method of human antithrombin III |
| CN105039295A (en) * | 2015-09-15 | 2015-11-11 | 上海洲跃生物科技有限公司 | Method for preparing human thrombin from cold-removing glue plasma |
| CN105175486A (en) * | 2015-10-20 | 2015-12-23 | 上海洲跃生物科技有限公司 | Preparation method of high-purity human coagulation factor IX |
Non-Patent Citations (2)
| Title |
|---|
| Chromatography in plasma fractionation: benefits and future trends;T. Burnouf;《Journal of Chromatography B 》;19951231;第664卷;全文 * |
| Possible Production of Prothrombin Complex Concentrate by Anion-Exchange Column Chromatography;A. V. Iserkapov 等;《Pharmaceutical Chemistry Journal》;20150331;第48卷(第12期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106676089A (en) | 2017-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106676089B (en) | Method for preparing human prothrombin complex from blood plasma | |
| CN104672328B (en) | A kind of production method of Human Antithrombin Ⅲ | |
| CA2220501C (en) | Novel factor ix purification methods | |
| AU2011234521B2 (en) | A process for purifying Vitamin K dependent proteins such as coagulation factor IX | |
| CN102228683B (en) | Method for preparing freeze-dried human blood coagulation factor VIII | |
| CN108048433B (en) | Preparation method of human prothrombin complex | |
| CN101974070B (en) | Preparation process of human prothrombin compound | |
| CN113563457B (en) | Method for simultaneously preparing human fibrinogen, blood coagulation factor VIII and plasminogen | |
| CN104328101A (en) | Preparation method of thrombin | |
| CN110257358B (en) | Production method of high-purity human coagulation factor IX preparation | |
| CN107827974B (en) | Preparation method of human fibrinogen | |
| CN109651502B (en) | Method for simultaneously separating and purifying blood coagulation factors IX, X and VII from human plasma | |
| CN106497903B (en) | A kind of technique for purifying blood coagulation proenzyme compound | |
| CN111500563B (en) | Method for purifying human coagulation factor VII from human plasma | |
| CN112480246A (en) | Separation and purification method of dog immunoglobulin and application thereof | |
| CN111849945A (en) | Method for purifying human blood coagulation factor VIIa | |
| CN101439047B (en) | Technological process for improving stable FVII yield of human prothrombin complexes | |
| CN109705208A (en) | A kind of technique of single step chromatography preparation high-purity vWF ELISA | |
| CN111378029B (en) | Preparation method of human coagulation factor IX | |
| CN108441490B (en) | Process for preparing human prothrombin complex by flow adsorption method | |
| JPH0794478B2 (en) | Method for preparing pharmaceutical composition containing vitamin K-dependent protein and immunoadsorbent used therefor | |
| CN115109142A (en) | Method for simultaneously separating canine fibrinogen and canine prothrombin complex from canine plasma | |
| CN108660126A (en) | A kind of preparation process of freeze dried human zymoplasm | |
| CN104744585B (en) | A kind of Expanded Bed Adsorption（EBA）Technology prepares the process of fibrinogen | |
| CN106520737A (en) | Method for purifying urokinase through resin regeneration column efficiency improvement |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |